Your browser doesn't support javascript.
loading
Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.
Charbogne, Pauline; Gardon, Olivier; Martín-García, Elena; Keyworth, Helen L; Matsui, Aya; Mechling, Anna E; Bienert, Thomas; Nasseef, Md Taufiq; Robé, Anne; Moquin, Luc; Darcq, Emmanuel; Ben Hamida, Sami; Robledo, Patricia; Matifas, Audrey; Befort, Katia; Gavériaux-Ruff, Claire; Harsan, Laura-Adela; von Elverfeldt, Dominik; Hennig, Jurgen; Gratton, Alain; Kitchen, Ian; Bailey, Alexis; Alvarez, Veronica A; Maldonado, Rafael; Kieffer, Brigitte L.
Afiliación
  • Charbogne P; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec,
  • Gardon O; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch.
  • Martín-García E; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain.
  • Keyworth HL; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom.
  • Matsui A; Section on Neuronal Structure, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.
  • Mechling AE; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Bienert T; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Nasseef MT; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Robé A; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch.
  • Moquin L; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Darcq E; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Ben Hamida S; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Robledo P; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain.
  • Matifas A; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch.
  • Befort K; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Laboratoire de Neurosciences Cognitives et Adaptatives, Université de Strasbourg Faculté de Psy
  • Gavériaux-Ruff C; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch.
  • Harsan LA; Laboratory of Engineering, Informatics and Imaging, Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg, Strasbourg, France; University Hospital Strasbourg, Department of Biophysics and Nuclear Medicine, Strasbourg, France; Department of Radiology, Medical Physics, Medic
  • von Elverfeldt D; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Hennig J; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Gratton A; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Kitchen I; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom.
  • Bailey A; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom; Institute of Medical and Biomedical Education, St. George's University of London, London, United Kingdom.
  • Alvarez VA; Section on Neuronal Structure, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.
  • Maldonado R; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain.
  • Kieffer BL; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec,
Biol Psychiatry ; 81(9): 778-788, 2017 05 01.
Article en En | MEDLINE | ID: mdl-28185645
ABSTRACT

BACKGROUND:

Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but underlying circuit mechanisms have been poorly explored by genetic approaches. Here we investigate the contribution of MORs expressed in gamma-aminobutyric acidergic forebrain neurons to major biological effects of opiates, and also challenge the canonical disinhibition model of opiate reward.

METHODS:

We used Dlx5/6-mediated recombination to create conditional Oprm1 mice in gamma-aminobutyric acidergic forebrain neurons. We characterized the genetic deletion by histology, electrophysiology, and microdialysis; probed neuronal activation by c-Fos immunohistochemistry and resting-state functional magnetic resonance imaging; and investigated main behavioral responses to opiates, including motivation to obtain heroin and palatable food.

RESULTS:

Mutant mice showed MOR transcript deletion mainly in the striatum. In the ventral tegmental area, local MOR activity was intact, and reduced activity was only observed at the level of striatonigral afferents. Heroin-induced neuronal activation was modified at both sites, and whole-brain functional networks were altered in live animals. Morphine analgesia was not altered, and neither was physical dependence to chronic morphine. In contrast, locomotor effects of heroin were abolished, and heroin-induced catalepsy was increased. Place preference to heroin was not modified, but remarkably, motivation to obtain heroin and palatable food was enhanced in operant self-administration procedures.

CONCLUSIONS:

Our study reveals dissociable MOR functions across mesocorticolimbic networks. Thus, beyond a well-established role in reward processing, operating at the level of local ventral tegmental area neurons, MORs also moderate motivation for appetitive stimuli within forebrain circuits that drive motivated behaviors.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Prosencéfalo / Receptores Opioides mu / Heroína / Conducta Alimentaria / Neuronas GABAérgicas / Motivación / Narcóticos Límite: Animals Idioma: En Revista: Biol Psychiatry Año: 2017 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Prosencéfalo / Receptores Opioides mu / Heroína / Conducta Alimentaria / Neuronas GABAérgicas / Motivación / Narcóticos Límite: Animals Idioma: En Revista: Biol Psychiatry Año: 2017 Tipo del documento: Article